相关实验视频

Updated: Jan 14, 2026

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation

Published on: May 16, 2016

设计一种宏分子JAK抑制剂,用于治疗急性炎症和内毒性血症

Min Zhou^1,2,3, Yan Wang¹, Bin Yang¹

¹Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing, China.

Nature biomedical engineering

|October 17, 2025

概括

一种新的宏分子疗法,HPL,通过抑制IL-6/JAK2/STAT3通路,有效地向炎症. 这种强大而安全的JAK2抑制剂在治疗炎症性疾病方面表现有前途.

科学领域:

生物材料科学生物材料科学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

慢性炎症驱动许多疾病,需要新的治疗策略.
目前的抗炎疗法往往缺乏足够的疗效或具有不良的副作用.
对于安全有效的抗炎疗法有着显著的未满足的需求.

研究的目的:

开发和描述一种新的宏分子疗法,HPL,用于治疗炎症疾病.
在临床前模型中评估HPL的抗炎疗效和安全性.
阐明HPL在减少炎症中的作用机制.

主要方法:

通过将聚乙烯糖醇和明醇结合成循环结构来合成HPL.
HPL自组装成细胞,向炎症组织和炎症细胞.
在急性肺,,肝损伤和内毒性病的小鼠模型中评估了抗炎作用.
通过分析IL-6/JAK2/STAT3信号通路来研究作用机制.
在小鼠中,在剂量明显高于治疗水平时评估了安全性.

主要成果:

在多种伤害模型中,HPL表现出强大的抗炎作用,与现有药物相比或优于现有药物.
HPL菌株有效向炎症组织和炎症细胞.
HPL抑制了IL-6/JAK2/STAT3信号通路,调解了它的抗炎作用.
在高剂量的小鼠中,HPL表现出良好的安全性.

结论:

HPL是一种强大的,自我组装的宏分子疗法,具有显著的抗炎活性.
HPL通过抑制IL-6/JAK2/STAT3通路而起作用,并显示出治疗炎症疾病的前景.
HPL代表了一种有前途,具有成本效益和安全的JAK2抑制剂,用于各种炎症状况.

更多相关视频

Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages

Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages

Published on: November 3, 2014

Highly Efficient Transfection of Human THP-1 Macrophages by Nucleofection

Highly Efficient Transfection of Human THP-1 Macrophages by Nucleofection

Published on: September 2, 2014

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...